The Securities and Exchange Commission has not necessarily
reviewed the information in this filing and has not determined
if it is accurate and complete.
| |||||||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| 8X8 INC NEW | COM | 282914100 | 1,694,354 | 990,850 | SH | DFND | 1 | 990,850 | 0 | 0 | |
| DENALI THERAPEUTICS INC | COM | 24823R105 | 49,144,027 | 1,910,732 | SH | DFND | 1 | 1,910,732 | 0 | 0 | |
| SANA BIOTECHNOLOGY INC | COM | 799566104 | 2,637,619 | 755,736 | SH | DFND | 1 | 755,736 | 0 | 0 | |